Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
the increase in lifespan in Western countries predicts that CNS diseases
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, the appropriate size range for DDS is between 100 and 200 nm.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
In the citing paper
“however, to be able to cross the BBB, the literature indicates that NPs should be smaller than 200 nm [24].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
Citations
Cites
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Lindgren, M., Hällbrink, M., Prochiantz, A., & Langel, Ü. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01447-4 · Cited by 803
Lin, T., Zhao, P., Jiang, Y., Tang, Y., Jin, H., Pan, Z., He, H., Yang, V. C., & Huang, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b04268 · Cited by 527
Wiley, D. T., Webster, P., Gale, A., & Davis, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307152110 · Cited by 519
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
The burden of neurological disease in theUnitedStates: A summary report and call to action
Gooch, C. L., Pracht, E., & Borenstein, A. R. (2017) · Annals of Neurology · doi:10.1002/ana.24897 · Cited by 388
Designing super selectivity in multivalent nano-particle binding
Martinez-Veracoechea, F. J., & Frenkel, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105351108 · Cited by 346
Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Research works printed but not linked: 1
- 10.3390/pharmaceutics10010034 · doi:10.3390/pharmaceutics10010034 · Paper page
Cited by
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 652
“Since endocytosis of NPs by the BBB endothelial cells seems to be predominantly mediated by receptors, many efforts have been made with SLN surface functionalization to enhance their CNS availability (Ceña and Játiva, 2018; Kuo et al., 2019; Wang et al., 2019), as discussed in Section 2 for the functionalized angiopep…”
BackgroundHersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
“Furthermore, by increasing the permeability of the BBB, NPs may also result in uptake of undesired toxic substances [79].”
BackgroundApplications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review
Ribeiro, A. I., Dias, A. M., & Zille, A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03891 · Cited by 276
Metadata
- Authors
- Ceña, V., & Játiva, P.
- Affiliations
- Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Albacete, Spain
- Instituto de Salud Carlos III (ES)
- ORCID
- Játiva, Pablo
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-07
- Volume
- 13
- Issue
- 13
- Pages
- 1513-1516
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2868168748
- Semantic Scholar
- f5267cc2f2cb4aee9679939ee9c77f593ddb94ac
- Cited by
- 232
- References
- 21
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 31 · 2023: 47 · 2022: 45 · 2021: 32 · 2020: 21 · 2019: 14 · 2018: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanomedicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- blood-brain barrier, nanoparticles, nanoparticle delivery, central nervous system disorders, brain drug delivery, neurodegenerative diseases, neuroinflammation
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Central Nervous System, Central Nervous System Diseases, Humans, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases. https://app.cochat.ai/papers/10.2217/nnm-2018-0139
- The paper
- Ceña, V., & Játiva, P. (2018). Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases. Nanomedicine. https://doi.org/10.2217/nnm-2018-0139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.